Lv11
20 积分 2023-06-05 加入
GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma
4小时前
已完结
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review
4小时前
已完结
Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis
29天前
已完结
Osimertinib is an effective epidermal growth factor receptor-tyrosine kinase inhibitor choice for lung cancer with epidermal growth factor receptor exon 18-25 kinase domain duplication: report of two cases
1个月前
已完结
Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders
1个月前
已完结
Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors
1个月前
已完结
A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients
1个月前
已完结
Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders
1个月前
已完结
Targeting YES1 Disrupts Mitotic Fidelity and Potentiates the Response to Taxanes in Triple-Negative Breast Cancer
1个月前
已完结
Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond
1个月前
已完结
皖公网安备34019202002308
